Bracco S.p.A.

https://www.bracco.com

Bracco Group is an Italian multinational company operating in the healthcare sector, recognized as a world leader in diagnostic imaging. Headquartered in Milan, Italy, the company's core mission is to improve people's lives by shaping the future of prevention and precision imaging. Founded in 1927, Bracco maintains a strong commitment to innovation and scientific advancement in healthcare.

The Group offers a comprehensive portfolio of products and services across three main business areas: imaging agents, medical technologies, and health services. Its key offerings include contrast agents for various diagnostic modalities such as X-ray, Computed Tomography (CT), Magnetic Resonance Imaging (MRI), ultrasound, and nuclear medicine. Additionally, Bracco develops and markets advanced medical devices and administration systems for contrast media, and provides healthcare services through its Centro Diagnostico Italiano (CDI) in Milan.

Led by President and CEO Diana Bracco, the company continues to drive innovation, investing approximately 10% of its imaging diagnostics turnover in research and development. Recent developments include Health Canada and EU approvals for its lower-dose MRI contrast agent, gadopiclenol (VUEWAY), and the launch of AI-powered software like AiMIFY. Bracco Group is privately held and operates globally, with a presence in over 100 countries, emphasizing sustainability and strategic partnerships to advance medical imaging.

Latest updates

Bracco Imaging Partners with NYU Langone to Accelerate Medical Imaging R&D

Event summary

  • Bracco Imaging and NYU Langone Health have entered into a multi-year Master Research Agreement (MRA) to advance medical imaging innovation.
  • The collaboration will focus on MRI, PCCT, targeted ultrasound, and AI-enabled PET/CT and MRI image analysis.
  • NYU Langone Health has consistently ranked among the top academic medical centers nationally, including #1 by Vizient for four consecutive years.
  • Bracco Imaging, with over 3,800 employees, operates in over 100 countries and generates revenue in the billions annually.

The big picture

This alliance reflects a broader trend of pharmaceutical companies partnering with leading academic institutions to accelerate innovation in medical imaging and capitalize on the growing demand for precision medicine solutions. The agreement allows Bracco to leverage NYU Langone’s research infrastructure and clinical expertise, while NYU Langone gains access to Bracco’s commercialization capabilities and contrast agent portfolio. The focus on AI-driven image analysis highlights the increasing importance of data science and machine learning in diagnostic imaging, a field attracting significant investment and driving rapid technological advancements.

What we're watching

Execution Risk
The success of the partnership hinges on the effective integration of Bracco’s contrast agent expertise with NYU Langone’s clinical and research capabilities, which could be challenging given differing organizational cultures and priorities.
Regulatory Headwinds
New AI-driven diagnostic tools developed through this collaboration will face increasing regulatory scrutiny, potentially delaying commercialization and impacting the partnership's return on investment.
Competitive Landscape
The partnership’s focus on PCCT and AI-enhanced imaging will intensify competition within the medical imaging space, requiring Bracco to differentiate its offerings and maintain a technological edge.

Bracco Gains Canadian Approval for Lower-Dose MRI Contrast Agent

Event summary

  • Bracco Imaging received Health Canada approval for VUEWAY® injection (gadopiclenol), a macrocyclic gadolinium-based contrast agent.
  • VUEWAY® requires a dose of 0.05 mmol/kg, half the standard dose of other GBCAs, reducing patient gadolinium exposure.
  • The approval follows prior approvals in the United States (2022) and the European Union (2023), bringing the total approved countries to 37.
  • Over 4 million patient doses of VUEWAY® have been administered globally.

The big picture

The approval of VUEWAY® reflects a growing emphasis on minimizing patient exposure to gadolinium and reducing the environmental impact of contrast agents. This trend is driven by increasing regulatory scrutiny and evolving clinical guidelines. Bracco’s collaboration with Guerbet, while accelerating development, also introduces a shared-ownership dynamic that could impact long-term profitability and strategic flexibility.

What we're watching

Market Adoption
The speed of VUEWAY’s adoption in Canada will depend on physician acceptance and reimbursement rates, potentially impacting Bracco’s overall revenue growth in the region.
Competitive Response
Other contrast agent manufacturers will likely respond to VUEWAY’s lower-dose approach, potentially leading to price pressure or the development of competing products with similar benefits.
IP Landscape
The ongoing collaboration and IP ownership structure between Bracco and Guerbet could create complexities and influence future commercialization strategies for gadopiclenol.

ASNC Endorsement Boosts Bracco's Cardiac PET Market Position

Event summary

  • The American Society of Nuclear Cardiology (ASNC) issued a position statement recommending cardiac PET myocardial perfusion imaging (MPI) with myocardial blood flow (MBF) quantification as the preferred modality for coronary artery disease (CAD) evaluation.
  • Bracco affirmed its support for the ASNC guidance, highlighting its three-decade leadership in cardiac PET.
  • The ASNC statement contrasts cardiac PET with SPECT imaging, citing PET's superior accuracy in detecting heart disease, assessing patient risk, and diagnosing complex cases.
  • Bracco’s cardiac PET portfolio includes Cardiogen-82 (Rubidium Rb 82 generator) and HeartSee™ software for blood flow quantification.

The big picture

The ASNC’s endorsement represents a significant validation of cardiac PET’s clinical utility and a potential shift away from SPECT imaging in CAD diagnosis. This move could accelerate the adoption of advanced diagnostic tools and benefit patients through more accurate assessments and personalized treatment plans. Bracco, as a long-standing leader in cardiac PET, is well-positioned to capitalize on this trend, but faces the challenge of driving widespread adoption and navigating potential reimbursement hurdles.

What we're watching

Adoption Rate
The speed at which clinical adoption of PET MPI with MBF increases following the ASNC endorsement will determine the immediate impact on Bracco’s revenue.
Reimbursement
Whether payers will rapidly adjust reimbursement policies to align with the ASNC recommendation will be crucial for widespread adoption and Bracco’s long-term growth.
Competitive Response
The extent to which competitors in the SPECT imaging space react to the ASNC guidance and attempt to counter the shift towards PET will shape the competitive landscape.

Bracco, Canon Medical Collaborate to Drive CEUS Adoption in Europe

Event summary

  • Bracco Imaging and Canon Medical Systems Europe are co-hosting a symposium on Contrast-Enhanced Ultrasound (CEUS) at the European Congress of Radiology (ECR) 2026 in Vienna, Austria.
  • The symposium, taking place March 5, 2026, will focus on accelerating CEUS adoption and integration into clinical workflows.
  • Key opinion leaders, including Adrian Lim, Thomas Fischer, and Maija Radzina, will present at the session.
  • The event aims to highlight CEUS’s role in improving diagnostic speed, quality, and efficiency within European radiology departments.

The big picture

The joint symposium signals a renewed push for Contrast-Enhanced Ultrasound (CEUS) adoption in Europe, a modality that has faced challenges in gaining widespread clinical acceptance despite its potential to improve diagnostic accuracy and efficiency. Bracco’s partnership with Canon Medical, a major player in medical imaging, suggests a coordinated strategy to overcome these hurdles and expand the market for CEUS agents and related equipment. This initiative reflects a broader trend toward value-based care and the increasing pressure on radiology departments to optimize workflows and improve patient outcomes.

What we're watching

Market Penetration
The success of the symposium will hinge on its ability to demonstrably shift clinical practice; CEUS adoption has been slower than initially predicted, and this event represents a concerted effort to accelerate that change.
Technological Convergence
Canon Medical's involvement suggests a deeper integration of CEUS technology with existing ultrasound platforms, and the long-term impact of this collaboration on device innovation warrants monitoring.
Reimbursement Landscape
Wider CEUS adoption will require favorable reimbursement policies across European healthcare systems; the symposium’s messaging will likely emphasize cost-effectiveness to influence these decisions.

Bracco Bolsters AI Imaging Portfolio with EU Launch, Avicenna.AI Partnership

Event summary

  • Bracco Imaging launched AiMIFY®, an AI-powered contrast enhancement software, in the European Union, developed in collaboration with Subtle Medical.
  • Bracco entered a strategic co-development and commercial partnership with Avicenna.AI to advance AI applications in contrast-enhanced computed tomography (CT).
  • The Avicenna.AI collaboration will focus on computer-aided detection and diagnosis in brain CT angiography, with FDA submission anticipated in 2H 2026.
  • Both initiatives will be showcased at the 2026 European Congress of Radiology (ECR).

The big picture

Bracco’s moves signal a broader trend of established medical device and pharmaceutical companies aggressively integrating AI to enhance diagnostic capabilities and streamline workflows. This partnership allows Bracco to expand beyond its core contrast agent business and compete more directly in the rapidly evolving AI-driven medical imaging market. The focus on CT angiography suggests a targeted approach to address a specific clinical need and potentially capture a significant share of a growing market.

What we're watching

Regulatory Approval
The timing and scope of the FDA submission for the Avicenna.AI CT applications will be a key indicator of the partnership’s progress and potential market entry in the US.
Integration Risk
Successful integration of Avicenna.AI’s interpretative AI into Bracco’s existing workflow and product portfolio will be crucial for realizing the partnership’s strategic benefits.
Competitive Response
How competitors in the diagnostic imaging space, particularly those with existing AI capabilities, will react to Bracco’s expanded AI offerings warrants close observation.

Bracco Showcases Integrated Imaging Portfolio at ECR 2026

Event summary

  • Bracco Imaging will unveil its integrated MRI portfolio at the European Congress of Radiology (ECR) in Vienna, March 4–8, 2026.
  • The company is collaborating with the European Society of Radiology (ESR) to host educational programs and symposiums focused on advancing radiology.
  • The MRI unveiling on March 5th will feature presentations from three international experts on breast imaging, pediatric neuroradiology, and brain MRI applications.
  • Bracco will showcase solutions spanning contrast media, injectors, medical devices, and AI software.
  • The event aligns with the ESR’s ‘Rays of Knowledge’ theme, emphasizing scientific exchange and responsible innovation.

The big picture

Bracco’s focus on integrated imaging solutions reflects a broader trend in the diagnostic imaging industry towards holistic, AI-powered platforms. The company's commitment to education and collaboration with the ESR signals an effort to shape the future of radiology and maintain a competitive edge in a market increasingly driven by data and personalized medicine. The unveiling of the MRI portfolio and related AI technologies represents a significant opportunity to solidify Bracco’s position as a leader in the €30 billion global contrast media market.

What we're watching

AI Integration
The adoption rate of Bracco's AiMIFY™ software will be a key indicator of its success in the competitive AI-driven medical imaging space, and its ability to drive adoption will influence future investment.
Regulatory Scrutiny
Increased regulatory focus on contrast agent safety and efficacy, particularly gadopiclenol, could impact Bracco’s market share and necessitate further investment in safer alternatives.
Partnership Dynamics
The long-term strategic value of Bracco’s partnership with the ESR will depend on its ability to leverage the collaboration for market access and influence industry standards.

Bracco Gains Pediatric MRI Edge with FDA Approval for VUEWAY

Event summary

  • Bracco received FDA approval to extend the use of VUEWAY® (gadopiclenol) for injection to neonates and infants.
  • VUEWAY delivers effective contrast enhancement at half the gadolinium dose (0.05 mmol/kg) compared to other macrocyclic GBCAs (0.1 mmol/kg).
  • Over 3.5 million doses of VUEWAY have been administered across approximately 900 customer sites in the U.S.
  • The approval was based on data from study GDX-44-015 evaluating safety and efficacy in pediatric patients.

The big picture

This approval positions Bracco favorably within the diagnostic imaging market, particularly as concerns around gadolinium deposition and patient safety drive demand for lower-dose contrast agents. The move aligns with a broader trend towards personalized medicine and minimizing patient exposure to potentially harmful substances, especially in vulnerable populations like neonates. While the market for pediatric MRI is smaller than adult imaging, it represents a high-value segment with a focus on long-term patient outcomes.

What we're watching

Adoption Rate
The speed of adoption among pediatric imaging centers will depend on clinician comfort with the lower dose and perceived impact on workflow.
Liability Risk
Bracco’s exposure to litigation related to gadolinium retention and NSF will be closely monitored, especially given the expanded pediatric indication.
Competitive Response
Other contrast agent manufacturers will likely respond with their own lower-dose formulations or marketing campaigns to maintain market share.

Bracco Expands Contrast Management Tech in Europe with ACIST Pro Launch

Event summary

  • Bracco Group launched the ACIST Pro™ Diagnostic System in select European markets on February 12, 2026.
  • The ACIST Pro™ system builds on the existing ACIST CVi® technology, automating contrast delivery in image-guided cardiovascular procedures.
  • Clinical data suggests the ACIST CVi® system reduces contrast use by 45ml, CI-AKI risk by 30%, and saves an average of 5 minutes per case.
  • The system was previously launched in Japan in 2025, and FDA 510(k) clearance is pending in the United States.
  • Bracco Imaging’s CEO, Fulvio Renoldi Bracco, highlighted the system's role in advancing precision imaging across specialties.

The big picture

The launch of ACIST Pro™ underscores the ongoing trend towards automation and precision in interventional cardiology, driven by a desire to improve patient outcomes and reduce healthcare costs. Bracco’s acquisition of ACIST positions them to capitalize on this trend, leveraging ACIST’s technology to complement Bracco’s broader diagnostic imaging portfolio. The system's success will be a key indicator of Bracco's ability to integrate acquired businesses and drive innovation within its medical device segment, which represents a significant portion of the company's €2 billion annual revenue.

What we're watching

Regulatory Headwinds
The success of ACIST Pro™ in Europe will depend on ongoing adherence to the MDR and potential future revisions to EU medical device regulations, which could impact market access and approval timelines.
US Adoption
The timing and outcome of the FDA 510(k) clearance process will be critical for broader market penetration, as the US represents a significant revenue opportunity for Bracco and ACIST.
Competitive Landscape
How effectively Bracco can differentiate ACIST Pro™ from competing contrast management systems, particularly as other players innovate in this space, will determine its long-term market share and profitability.

Bracco Gains EU Approval to Expand Contrast Agent Use in Infants

Event summary

  • The European Commission extended the Marketing Authorisation for Bracco’s Vueway® (gadopiclenol) to include pediatric patients under 2 years of age, effective January 23, 2026.
  • This approval followed a positive opinion from the CHMP and a recommendation from the EMA.
  • Vueway® is approved in 36 countries and used for MRI contrast enhancement.
  • Clinical studies indicate Vueway® delivers comparable diagnostic efficacy at half the gadolinium dose of gadobutrol.
  • Bracco and Guerbet have a collaboration for Gadopiclenol manufacturing and R&D, with both companies expected to manufacture the active ingredient and finished product after a transition period.

The big picture

This approval represents a strategic win for Bracco, expanding the addressable market for Vueway® and reinforcing its position as a leader in advanced diagnostic imaging. The move to lower-dose imaging reflects growing concerns about gadolinium retention and its potential long-term health effects, a trend likely to shape future regulatory decisions and product development in the contrast agent market. The collaboration with Guerbet, while complex, positions both companies to capitalize on the growing demand for innovative imaging solutions.

What we're watching

Adoption Rate
The speed of adoption among pediatric radiologists and the impact on overall Vueway® sales will be key indicators of the approval’s success.
Liability Risk
The long-term safety profile of gadolinium exposure in neonates will be closely scrutinized, potentially leading to further regulatory action or litigation.
Competitive Response
Guerbet and other contrast agent manufacturers will likely accelerate their own R&D efforts to compete with Vueway®’s expanded indication and lower dosage.

Bracco Gains EU Approval to Expand Contrast Agent Use in Infants

Event summary

  • The European Commission approved an extension of the Marketing Authorisation for Bracco’s Vueway® (gadopiclenol) to include pediatric patients under 2 years of age, effective January 23, 2026.
  • The approval followed a positive opinion from the CHMP and a recommendation from the EMA.
  • Vueway® is a macrocyclic gadolinium-based contrast agent approved in 36 countries, previously approved for use in adults and children over 2 years old.
  • Clinical studies (GDX-44-015) demonstrated Vueway® can achieve comparable diagnostic efficacy at half the gadolinium dose of gadobutrol.

The big picture

This approval underscores the increasing scrutiny and refinement of contrast agent usage, particularly in vulnerable patient populations. The ability to reduce gadolinium exposure while maintaining diagnostic efficacy is a key differentiator in a market facing growing concerns about gadolinium deposition. Bracco’s collaboration with Guerbet creates a complex dynamic, balancing shared intellectual property with independent commercialization strategies.

What we're watching

Adoption Rate
The speed at which pediatricians and radiologists adopt Vueway® for younger patients will determine the extent of Bracco’s revenue gains in this new segment.
Competitive Response
Guerbet, with whom Bracco has a manufacturing collaboration, may accelerate development of competing products or strategies to maintain its position in the contrast agent market.
Liability Risk
Long-term monitoring of patient outcomes in this expanded pediatric population will be crucial to identify and mitigate any unforeseen adverse effects related to gadolinium retention.

Bracco's Vueway Expansion Targets Neonates, Bolsters Contrast Agent Portfolio

Event summary

  • The European Medicines Agency's (EMA) CHMP issued a positive opinion on December 11, 2025, extending the approved indications of Bracco's Vueway® (gadopiclenol) to pediatric patients under 2 years of age.
  • Vueway® is a macrocyclic gadolinium-based contrast agent (GBCA) already approved in 36 countries and used in MRI examinations.
  • Clinical studies indicate Vueway® delivers comparable diagnostic efficacy at half the gadolinium dose of gadobutrol.
  • Bracco and Guerbet have a collaboration for Gadopiclenol manufacturing and R&D, with both companies expected to manufacture the active ingredient and finished product after a transition period.

The big picture

This approval represents a strategic win for Bracco, expanding the addressable market for Vueway® and reinforcing its position as a leader in contrast agents. The lower dosage requirement, compared to competitors like gadobutrol, addresses growing concerns about gadolinium deposition and aligns with a trend toward minimizing patient exposure to contrast agents. The collaboration with Guerbet, while complex, positions Bracco to capitalize on the increased demand and potentially scale production efficiently.

What we're watching

Adoption Rate
The speed of adoption among pediatric radiologists will depend on clinical guidelines and perceived safety benefits, potentially impacting Vueway’s revenue growth in this new segment.
Liability Risk
Given ongoing concerns about gadolinium retention, Bracco will need to proactively manage any adverse event reporting and demonstrate continued safety in this vulnerable patient population.
Competitive Response
Other contrast agent manufacturers may accelerate their own development programs for pediatric formulations, intensifying competition and potentially eroding Bracco’s market share gains.
CID: 253